Genotoxicity induced by iodine-131 in human cultured lymphocytes
Open Access
|Aug 2013References
- Ballardin M, Gemignani F, Bodei L, Mariani G, Ferdeghini M, Rossi AM, Migliore L, Barale R. (2002). Formation of micronuclei and of clastogenic factor(s) in patients receiving therapeutic doses of iodine-131.(1-2): 77-85.
- de Vathaire F, Schlumberger M, Delisle MJ, Francese C, Challeton C, de la Genardiere E, Meunier F, Parmentier C, Hill C, Sancho-Garnier H. (1997). Leukaemias and cancers following iodine-131 administration for thyroid cancer.(5): 734-739.
- Edmonds CJ, Smith T. (1986). The long-term hazards of the treatment of thyroid cancer with radioiodine.(697): 45-51.
- Fallahi B, Adabi K, Majidi M, Fard-Esfahani A, Heshmat R, Larijani B, Haghpanah V. (2011). Incidence of second primary malignancies during a longterm surveillance of patients with differentiated thyroid carcinoma in relation to radioiodine treatment.(4): 277-282.
- Fenech M. (2000). Themicronucleus technique.(1-2): 81-95.
- Grudeva-Popova J, Yaneva M, Zisov K, Ananoshtev N. (2007). Therapy-related acute promyelocytic leukemia after treatment with radioiodine for thyroid cancer: case report with literature review.(1): 129-132.
- Gutierrez S, Carbonell E, Galofre P, Creus A, Marcos R. (1997). Micronuclei induction by 131I exposure: study in hyperthyroidism patients.(1): 39-45.
- Hosseinimehr SJ. (2010). Flavonoids and genomic instability induced by ionizing radiation.(21-22): 907-918.
- Iyer NG, Morris LG, Tuttle RM, Shaha AR, Ganly I. (2011). Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy.(19): 4439-4446.
- Kolade VO, Bosinski TJ, Ruffy EL. (2005). Acute promyelocytic leukemia after iodine-131 therapy for Graves’ disease.(7): 1017-1020.
- Little JB. (2000). Radiation carcinogenesis.(3): 397-404.
- Monteiro Gil O, Oliveira NG, Rodrigues AS, Laires A, Ferreira TC, Limbert E, Leonard A, Gerber G, Rueff J. (2000). Cytogenetic alterations and oxidative stress in thyroid cancer patients after iodine-131 therapy.(1): 69-75.
- Robbins RJ, Schlumberger MJ. (2005). The evolving role of (131)I for the treatment of differentiated thyroid carcinoma.Suppl 1: 28S-37S.
- Sawka AM, Thabane L, Parlea L, Ibrahim-Zada I, Tsang RW, Brierley JD, Straus S, Ezzat S, Goldstein DP. (2009). Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis.(5): 451-457.
- Schroeder T, Kuendgen A, Kayser S, Kroger N, Braulke F, Platzbecker U, Klarner V, Zohren F, Haase D, Stadler M, Schlenk R, Czibere AG, Bruns I, Fenk R, Gattermann N, Haas R, Kobbe G, Germing U. (2012). Therapy-related myeloid neoplasms following treatment with radioiodine.(2): 206-212.
- Watanabe N, Kanegane H, Kinuya S, Shuke N, Yokoyama K, Kato H, Tomizawa G, Shimizu M, Funada H, Seto H. (2004). The radiotoxicity of 131I therapy of thyroid cancer: assessment by micronucleus assay of B lymphocytes.(4): 608-611.
Language: English
Page range: 74 - 76
Published on: Aug 24, 2013
Published by: Slovak Academy of Sciences, Institute of Experimental Pharmacology & Toxicology, Centre of Experimental Medicine
In partnership with: Paradigm Publishing Services
Keywords:
Related subjects:
© 2013 Seyed Jalal Hosseinimehr, Nayereh Shafaghati, Monireh Hedayati, published by Slovak Academy of Sciences, Institute of Experimental Pharmacology & Toxicology, Centre of Experimental Medicine
This work is licensed under the Creative Commons License.